Ariad Pharmaceuticals
E387618
Ariad Pharmaceuticals was a biotechnology company focused on developing targeted therapies for cancer and other serious diseases.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ariad Pharmaceuticals canonical | 1 |
Statements (43)
| Predicate | Object |
|---|---|
| instanceOf | biotechnology company ⓘ |
| acquiredBy | Takeda Pharmaceutical Company ⓘ |
| acquisitionAnnouncementDate | 2017-01 ⓘ |
| acquisitionCompletionDate | 2017-02 ⓘ |
| acquisitionValueUSD | 5200000000 ⓘ |
| brigatinibBrandName | Alunbrig ⓘ |
| brigatinibIndication | ALK-positive non-small cell lung cancer ⓘ |
| businessModel | research and development of small-molecule drugs ⓘ |
| collaboration | Merck & Co. ⓘ |
| collaborationType | drug discovery and development ⓘ |
| country |
United States of America
ⓘ
surface form:
United States
|
| defunctReason | acquisition by Takeda Pharmaceutical Company ⓘ |
| employeeType | scientists and researchers ⓘ |
| focus |
targeted cancer therapies
ⓘ
treatments for serious diseases ⓘ |
| foundedBy | Harvey J. Berger NERFINISHED ⓘ |
| foundingDate | 1991 ⓘ |
| headquartersLocation | Cambridge, Massachusetts ⓘ |
| IclusigRegulatoryEvent |
label updates with safety warnings
ⓘ
temporary marketing suspension in 2013 due to safety concerns ⓘ |
| industry |
biotechnology
ⓘ
pharmaceuticals ⓘ |
| keyPerson |
Harvey J. Berger
NERFINISHED
ⓘ
Paris Panayiotopoulos ⓘ |
| keyPersonRole | Chief Executive Officer ⓘ |
| location |
Massachusetts
ⓘ
United States of America ⓘ
surface form:
United States
|
| notableProduct |
brigatinib
ⓘ
ponatinib ⓘ |
| Paris PanayiotopoulosRole | Chief Executive Officer ⓘ |
| ponatinibBrandName | Iclusig ⓘ |
| ponatinibIndication |
Philadelphia chromosome–positive acute lymphoblastic leukemia
ⓘ
chronic myeloid leukemia ⓘ |
| regulatoryBodyInteraction |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| regulatoryRegion |
European Union
ⓘ
United States of America ⓘ
surface form:
United States
|
| researchArea |
oncology
ⓘ
signal transduction inhibitors ⓘ tyrosine kinase inhibitors ⓘ |
| status | defunct ⓘ |
| therapeuticClass | oncology therapeutics ⓘ |
| tickerSymbol | ARIA ⓘ |
| tradedOn | NASDAQ ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.